Brind.

Avita Medical received FDA approval for its RECELL System, granting it exclusive U.S. market rights.

4 reports, 2 independent Updated Aug 7

Gone quiet

Reports: 4
Developments: 2
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Avita Medical received FDA approval for its RECELL System, granting it exclusive U.S. market rights.

Who's involved

What this event is mainly about

Avita Medical FDA

How it developed

Newest first. Tap a step to see who reported it.

Aug 22Avita Medical's RECELL System received FDA approval, securing exclusive U.S. market rights.1 source
- GlobeNewswire
Aug 8CMS granted NTAP status for Avita's RECELL System, and Avita made corporate changes.1 source
- GlobeNewswire

Keep exploring

The entities involved

Avita Medical
Australian public company

Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Coverage

Newest first; wire copies grouped

Aug 7manilatimes.net
Aug 22GlobeNewswireAVITA Medical Announces September Investor Conference Participation VALENCIA, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound
Aug 8GlobeNewswireAVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation VALENCIA, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical
Jul 29GlobeNewswireAVITA Medical to Announce Second Quarter 2025 Financial Results VALENCIA, Calif. and MELBOURNE, Australia, July 28, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading th